Iterum Therapeutics plc - Ordinary Share (ITRM)

Iterum Therapeutics (ITRM) Earnings Transcript

Iterum Therapeutics stock plunges after Q3 2025 earnings miss estimates, with a wider-than-expected loss overshadowing its new product launch.

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.

Iterum Therapeutics PLC reports Q2 2025 earnings with a wider loss than expected, but stock rises 4.15% pre-market as investors anticipate ORLYNVAH's August 2025 launch. Cash reserves extend into 2026.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade tariffs eroded risk appetite.

Iterum Therapeutics' Orlynvah receives FDA approval for treating uncomplicated UTIs in adult women, marking its first approved indication and a U.S. first for oral penems.

ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.